PMID- 37164159
OWN - NLM
STAT- MEDLINE
DCOM- 20230606
LR  - 20230606
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Print)
IS  - 0168-8227 (Linking)
VI  - 200
DP  - 2023 Jun
TI  - The effectiveness of COVID-19 vaccination against all-cause mortality in patients 
      with type 2 diabetes mellitus: The observation during the initial period of the 
      cancellation of the "Dynamic Zero Policy" in mainland China.
PG  - 110694
LID - S0168-8227(23)00457-6 [pii]
LID - 10.1016/j.diabres.2023.110694 [doi]
AB  - AIMS: This study aims to assess the effectiveness of COVID-19 vaccination against 
      all-cause death in patients with type 2 diabetes mellitus (T2DM). METHODS: 
      Subjects were patients with T2DM who were administered by general practitioner 
      (GP). Use electronic exchange platform to obtain the information on COVID-19 
      vaccination, all-cause deaths and risk factors. Logistic regression models were 
      used to calculate the odd ratio (OR) and 95% CI for the association between 
      COVID-19 vaccination and mortality. The vaccine effectiveness (VE) was calculated 
      as (1- adjusted OR) x 100%. RESULTS: A total of 26,916 subjects had 53.81%, 
      17.65%, and 23.43% coverage for the booster, full, and partial COVID-19 
      vaccination, reported 328 deaths and a mortality of 1.2%. The adjusted OR (95%CI) 
      was 0.85(0.60-1.21) for those received partial vaccination, 0.31(0.22-0.43) for 
      those received full vaccination, and 0.12(0.08-0.18) for those received booster 
      vaccination, compared to the unvaccinated individuals. The VE (95%CI) was 
      88.00%(82.30-91.80) of booster vaccination, 69.30%(56.60-78.30) of full 
      vaccination, and 17.60%(-17.10-42.00) of partial vaccination. CONCLUSION: 
      COVID-19 vaccination could effectively prevent the all-cause death in patients 
      with T2DM during the omicron variant outbreak period, after the cancellation of 
      the "Dynamic Zero Policy" in mainland China.
CI  - Copyright (c) 2023 Elsevier B.V. All rights reserved.
FAU - Liu, Shijun
AU  - Liu S
AD  - HangZhou Center for Disease Control and Prevention, HangZhou, ZheJiang, China. 
      Electronic address: shijun9170@sina.com.
FAU - Jiang, Caixia
AU  - Jiang C
AD  - HangZhou Center for Disease Control and Prevention, HangZhou, ZheJiang, China.
FAU - Liu, Yan
AU  - Liu Y
AD  - HangZhou Center for Disease Control and Prevention, HangZhou, ZheJiang, China.
FAU - Zhang, Yan
AU  - Zhang Y
AD  - HangZhou Center for Disease Control and Prevention, HangZhou, ZheJiang, China.
FAU - Qiu, Xin
AU  - Qiu X
AD  - HangZhou Center for Disease Control and Prevention, HangZhou, ZheJiang, China.
FAU - Luo, Jun
AU  - Luo J
AD  - HangZhou Center for Disease Control and Prevention, HangZhou, ZheJiang, China.
FAU - Xu, Yuyang
AU  - Xu Y
AD  - HangZhou Center for Disease Control and Prevention, HangZhou, ZheJiang, China.
FAU - Wang, Jing
AU  - Wang J
AD  - HangZhou Center for Disease Control and Prevention, HangZhou, ZheJiang, China.
LA  - eng
PT  - Journal Article
DEP - 20230508
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (COVID-19 Vaccines)
RN  - SARS-CoV-2 variants
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2
MH  - COVID-19 Vaccines/therapeutic use
MH  - *COVID-19/epidemiology/prevention & control
MH  - SARS-CoV-2
MH  - China/epidemiology
MH  - Policy
MH  - Vaccination
PMC - PMC10165863
OTO - NOTNLM
OT  - All-cause death
OT  - COVID-19 vaccination
OT  - SARS-CoV-2
OT  - Type 2 diabetes mellitus
OT  - Vaccine effectiveness
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/05/11 00:41
MHDA- 2023/06/06 06:42
PMCR- 2023/05/08
CRDT- 2023/05/10 19:24
PHST- 2023/03/13 00:00 [received]
PHST- 2023/04/21 00:00 [revised]
PHST- 2023/05/02 00:00 [accepted]
PHST- 2023/06/06 06:42 [medline]
PHST- 2023/05/11 00:41 [pubmed]
PHST- 2023/05/10 19:24 [entrez]
PHST- 2023/05/08 00:00 [pmc-release]
AID - S0168-8227(23)00457-6 [pii]
AID - 110694 [pii]
AID - 10.1016/j.diabres.2023.110694 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2023 Jun;200:110694. doi: 10.1016/j.diabres.2023.110694. 
      Epub 2023 May 8.